A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

ClinicalTrials.gov ID: NCT07701993

Public ClinicalTrials.gov record NCT07701993. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Study identification

NCT ID: NCT07701993
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 1,740 participants

Conditions and interventions

Conditions

Metabolic Dysfunction-associated Steatohepatitis

Interventions

Efimosfermin alfa Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 22, 2026 (Actual)
Primary completion: Jun 23, 2033 (Estimated)
Completion: Aug 24, 2033 (Estimated)
Last update posted: Sep 30, 2026

2026 – 2033

United States locations

U.S. sites: 13
U.S. states: 5
U.S. cities: 11

Facility	City	State	ZIP	Site status
GSK Investigational Site	Little Rock	Arkansas	72211	Recruiting
GSK Investigational Site	Folsom	California	95630	Recruiting
GSK Investigational Site	Miami	Florida	33135-4661	Recruiting
GSK Investigational Site	Miami	Florida	33155	Recruiting
GSK Investigational Site	Ocala	Florida	34471	Recruiting
GSK Investigational Site	St Louis	Missouri	63141	Recruiting
GSK Investigational Site	Arlington	Texas	76012	Recruiting
GSK Investigational Site	Austin	Texas	78745-5675	Recruiting
GSK Investigational Site	Bellaire	Texas	77401	Recruiting
GSK Investigational Site	Dallas	Texas	75243-1921	Recruiting
GSK Investigational Site	Humble	Texas	77346	Recruiting
GSK Investigational Site	San Antonio	Texas	78209	Recruiting
GSK Investigational Site	San Antonio	Texas	78215	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07701993, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07701993 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →